photo: Hermann Gröhe at his speech in front of the public

Public Health 

The national Public Health and Veterinary Public Health-Institutes of the G20 countries met for the first time in Berlin. The meeting is a result of the declaration of the G20 health ministers in Berlin in May 2017.

 
photo: Two hands in blue gloves hold a petri dish with liquid in it and a syringe

First 'priority pathogens' list 

Responding to an initiative from the Federal Ministry of Health, the World Health Organization (WHO) published the first ever list of resistant bacteria that currently pose the greatest threat to human health.  

Screenshot of a film screen with a globe and coloruful ribbons flowing towards the viewer

G20 Summit Film

Pandemic outbreaks are huge challenges for the global community. Therefore, one priority of the German G20 presidency is global health. This is also the topic of the film showing impressions from the G20 Summit.

photo: view into the conference room of the G20 summit; participants sitting around a table, a video screen and flags of the country in the background

G20 Leaders' Declaration

The heads of state and government of the G20 underlined their joint final declaration of "Shaping an interconnected world", highlighting the important results of the G20 health ministry meeting in Berlin

photo: someone working in a laboratory

Supporting GARDP

Germany together with a number of countries and foundations pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP)

screenshot of the landing page with some articles and a photo of chancellor Angela Merkel

www.g20germany.de

At the Federal Government's official website on the German G20 Presidency you will find, inter alia, the latest news, programme priorities and dates.

A novel antibiotic

Thanks to the Global Antibiotic Research and Development Partnership, a novel antibiotic that is expected to improve the treatment of drug-resistant strains of gonorrhoea has entered the final, pivotal trials.